- A new analysis suggests the weight-loss jab Wegovy may carry the highest risk of sudden sight loss, known as an “eye stroke,” compared to similar medications like Ozempic.
- The study, published in the British Journal of Ophthalmology, found that men were three times more likely than women to experience this condition, ischaemic optic neuropathy (Ion).
- Researchers analysed over 30 million adverse event reports submitted to the U.S. FDA, concluding that the Ion risk appears dose and formulation dependent, being highest with Wegovy.
- Despite fewer overall reports for Wegovy compared to Ozempic, the analysis indicated the odds of Ion were almost five times higher with Wegovy.
- Novo Nordisk, the manufacturer, stated that patient safety is a priority and updated patient leaflets, but maintains there is no reasonable possibility of a causal link and the benefit-risk profile remains favourable.
IN FULL